CTOs on the Move

MiraVista Behavioral Health Center

www.miravistabhc.care

 
MiraVista is a new behavioral health treatment center opening April 2021 in the former Providence Hospital in Holyoke, MA. The newly renovated center will initially provide adult psychiatric and addiction treatment and will expand capacity to include child and adolescent services by the end of the year. Our mission is to provide compassionate, effective, sustainable care for those suffering from psychiatric distress and substance abuse. We are committed to helping fill the critical need for quality behavioral care in the Pioneer Valley and are excited to open our doors this Spring.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Hemispherx Biopharma

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, which is under clinical development for the treatment of Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging viral diseases. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

C.W. Juhl Consulting

C.W. Juhl Consulting is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Treatment Solutions Network

Treatment Solutions Network is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southern KY AHEC

Southern KY AHEC is a Mount Vernon, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nymox

NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.